

RECEIVED  
CENTRAL FAX CENTER

F A C S I M I L E		APR 14 2004
Date: April 14, 2004	From: JAMES E. RULAND	<b>OFFICIAL</b>
To: Examiner Brian Yong S. Kwon Group Art Unit 1614 U.S. Patent and Trademark Office	MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd., Suite 400 Arlington, VA 22201 (U.S.A.) (Fax: 703-243-6410)	
Facsimile No.: (703) 872-9306	Writer's Direct Dial: 703-812-5318	
Telephone No.: (703) 308-5377	Writer's Internet Address: <a href="mailto:ruland@mww.com">ruland@mww.com</a>	
<p>Re: U.S. Patent Application No. 09/838,286 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS P38 KINASE INHIBITORS Our Ref: BAYER-14</p>		
Total No. of Pages: 29; if you do not receive all pages, please call (703) 243-6333		

Dear Sir:

Applicants acknowledge Examiner Kwon's time and courtesy during the March 31, 2004, teleconference with applicants' representative James E. Ruland. Per that telephone conference, attached is a copy of the latest version of claims from U.S. Patent Application Serial No. 10/125,369.

Also attached is an Information Disclosure Statement with a Form PTO 1449. After reviewing the claims, applicants respectfully request the Examiner to initial the form and return it with the next paper from the Office.

If there are any remaining issues which can be expedited by a telephone conference, the Examiner is courteously invited to telephone counsel at the number indicated below.

Respectfully submitted,

James E. Ruland, Reg. No. 37,432  
Attorney for Applicants

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to (571) 273-0677 to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on.	
<u>April 14, 2004</u>	
Name: <u>Sharon McDaniel</u>	Signature: <u>Sharon McDaniel</u>
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.	

4.1.2004 05:12pm

Information contained in this facsimile may contain privileged and confidential information and is intended solely for the use of the addressee(s) listed above. If you are neither the intended recipient nor the employee or agent responsible for delivering this communication to the intended recipient, you are hereby advised that any disclosure, copying or distribution of, or the taking of any action in reliance on the contents of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone on (703) 243-6333 to arrange for return of the original document to us at our earliest. Thank you.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Jacques DUMAS et al.

Confirmation No.: 9096

Serial No.: 09/838,286

Examiner: Brian Yong S. Kwon

Filed: April 20, 2001

Group Art Unit: 1614

Title: HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS P38 KINASE INHIBITORS

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

**TIMING AND FEES**

Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:

- within three months of the filing date of a national application other than a CPA under § 1.53(d);
- within three months of the actual filing date of the national phase of a PCT application; OR
- before the mailing of a first substantive office action (including after filing of an RCE).

Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

- a final rejection under 37 C.F.R. § 1.113;
- termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(3)(2); OR
- a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

- the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
- a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:

- a final action under 37 C.F.R. § 1.113;
- termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(B)(2); OR
- a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

- the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

#### STATEMENTS UNDER 37 C.F.R. 1.97(e)

- Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

#### CITED MATERIALS

- Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. \_\_\_\_\_, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- Copies of materials listed but not attached were cited in an international search report dated \_\_\_\_\_.
- Copies of the materials listed are attached (except for the foregoing).

#### NON-ENGLISH LANGUAGE REFERENCES

- An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
- A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone  
Y = document of particular relevance when it is combined with another such document  
A = document defining the general state of the art  
O = non-written disclosure  
P = intercalated document  
T = document cited to understand the theory or principle underlying the invention  
E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date  
D = cited in the application  
L = cited for another reason  
& = publication of member of same patent family

Translation of other relevant information on foreign search report

#### OTHER INFORMATION

None

**PAYMENT OF FEES DUE (IF ANY):**

A check for \$\_\_\_\_\_ covering the fee identified above is attached.

Please charge to Deposit Account No. 13-3402 \$\_\_\_\_\_ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account No. 13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

**James E. Ruland, Reg. No. 37,412  
Attorney for Applicants**

MILLEN, WHITE, ZELANO &  
BRANIGAN, P.C.

~~Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410~~

Attorney Docket No.: BAYER-14

Date: April 14, 2004

Please type a plus sign (+) inside this box → 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					
(use as many sheets as necessary)					
Sheet	1	of	1	Attorney Docket Number	BAYER-14

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant or Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>2</sup>	Number <sup>3</sup>		
A1					
A2					
A3					
A4					
A5					
A6					
A7					

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>2</sup>	Number <sup>3</sup>		
B1					
B2					
B3					
B4					
B5					
B6					
B7					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	C1	September 11, 2003, claims of U.S. Patent Application Serial No. 10/125,369, filed April 19, 2002, of Dumas et al.			
	C2				
	C3				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents <sup>3</sup> Enter Office that issued the document. By the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.